Table 1.
Micronutrient dose per 16 capsules (actual daily dose) of indicated micronutrients in control or treatment supplements.
Fig 1.
Enrollment, eligibility screening, allocation, follow-up, and analysis of participants in the MAINTAIN Randomized Controlled Trial.
Table 2.
Demographic and clinical characteristics for randomized participants at baseline (n = 171).
Table 3.
Number of MAINTAIN participants with micronutrient deficiencies over the study period (n = 171)1.
Fig 2.
Kaplan-Meier Curve: Time to confirmed* (*in 2 measures) CD4 T lymphocyte count decline below 350 cells/μL.
Week 0 includes all individuals who were screened in and allocated to a group. The table beneath shows the individuals remaining at risk at each time point and then number of individuals experiencing an event in that interval is in brackets. There were 11 events in the Control and 16 events in the Treatment group over the study period of 96 weeks.
Fig 3.
Kaplan-Meier Curve: Time to start of ART regardless of CD4 T lymphocyte count.
Week 0 includes all individuals who were screened in and allocated to a group. The table beneath shows the individuals remaining at risk at each time point and the number of individuals remaining at risk at each time point and the number of individuals experiencing an event in that interval is in brackets. There were 29 events in the Control group and 28 events in the Treatment group over the study period of 96 weeks.
Fig 4.
Kaplan-Meier Curve: Time to any primary outcome event.
Week 0 includes all individuals who were screened in allocated to a group (CD4<350, ART, AIDS or death). The table beneath shows the individuals remaining at risk at each time point and the number of individuals experiencing an event at that time point is in brackets. There were 32 events in the Control group and 34 events in the Treatment group over the study period of 96 weeks.